PT - JOURNAL ARTICLE AU - Lenehan, Patrick AU - Ramudu, Eshwan AU - Venkatakrishnan, AJ AU - Berner, Gabriela AU - McMurry, Reid AU - O’Horo, John C. AU - Badley, Andrew D. AU - Morice, William AU - Halamka, John AU - Soundararajan, Venky TI - Anemia is a risk factor for rehospitalization after SARS-CoV-2 clearance AID - 10.1101/2020.12.02.20242958 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.02.20242958 4099 - http://medrxiv.org/content/early/2021/01/19/2020.12.02.20242958.short 4100 - http://medrxiv.org/content/early/2021/01/19/2020.12.02.20242958.full AB - Background As the number of new and recovering COVID-19 cases continues to rise, it has become evident that patients can experience symptoms and complications after viral clearance. Clinical biomarkers characterizing patients who are likely to experience these prolonged effects are unknown.Methods We conducted a retrospective study to compare longitudinal lab test measurements (hemoglobin, hematocrit, estimated glomerular filtration rate, serum creatinine, and blood urea nitrogen) in patients rehospitalized after PCR-confirmed SARS-CoV-2 clearance (n=104) versus patients not rehospitalized after viral clearance (n=278).Findings Compared to patients who were not rehospitalized after PCR-confirmed viral clearance, those who were rehospitalized had lower median hemoglobin levels in the year prior to COVID-19 diagnosis (cohen’s D = -0.50; p=1.2×10−3) and during the active infection window (cohen’s D = -0.71; p=4.6×10−8). Patients hospitalized after viral clearance were also more likely to be diagnosed with moderate or severe anemia during the active infection window (OR = 2.18; p = 4.99×10−9).Conclusions The occurrence of moderate or severe anemia in hospitalized COVID-19 patients is strongly associated with rehospitalization after viral clearance. Whether interventions to mitigate anemia can improve long term outcomes of COVID-19 patients should be further investigated.Funding This study was funded by nference.Competing Interest StatementPL, ER, AV, GB, RM, and VS are employees of nference and have financial interests in the company. ADB is a consultant for Abbvie, is on scientific advisory boards for nference and Zentalis, is founder and President of Splissen therapeutics. One or more of the investigators associated with this project from the Mayo Clinic and the Mayo Clinic have a Financial Conflict of Interest in technology used in the research. The investigator(s) and Mayo Clinic may stand to gain financially from the successful outcome of the research. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.Funding StatementThis study was funded primarily by nference. ADB is supported by Grants AI 110173 and AI120698 from NIAID, 109593-62-RGRL from Amfar, and the HH Sheikh Khalifa Bin Zayed Al-Nahyan named professorship from Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study was reviewed and approved by the Mayo Clinic Institutional Review Board (IRB 20-003278) as a minimal risk study. Subjects were excluded if they did not have a research authorization on file.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter publication, the data will be made available to others upon reasonable requests to the corresponding author. A proposal with a detailed description of study objectives and the statistical analysis plan will be needed for evaluation of the reasonability of requests. Deidentified data will be provided after approval from the corresponding author and Mayo Clinic.